Literature DB >> 33933294

Congenital asymmetric distal myopathy with hemifacial weakness caused by a heterozygous large de novo mosaic deletion in nebulin.

Lydia Sagath1, Vilma-Lotta Lehtokari2, Salla Välipakka2, Anna Vihola3, Maria Gardberg4, Peter Hackman2, Katarina Pelin5, Manu Jokela6, Kirsi Kiiski7, Bjarne Udd8, Carina Wallgren-Pettersson2.   

Abstract

We report the first mosaic mutation, a deletion of exons 11-107, identified in the nebulin gene in a Finnish patient presenting with a predominantly distal congenital myopathy and asymmetric muscle weakness. The female patient is ambulant and currently 26 years old. Muscle biopsies showed myopathic features with type 1 fibre predominance, strikingly hypotrophic type 2 fibres and central nuclei, but no nemaline bodies. The deletion was detected in a copy number variation analysis based on next-generation sequencing data. The parents of the patient did not carry the deletion. Mosaicism was detected using a custom, targeted comparative genomic hybridisation array. Expression of the truncated allele, less than half the size of full-length nebulin, was confirmed by Western blotting. The clinical and histological picture resembled that of a family with a slightly smaller deletion, and that in patients with recessively inherited distal forms of nebulin-caused myopathy. Asymmetry, however, was a novel feature.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Copy number variation; Large deletion; Mosaicism; Nebulin; de novo mutation

Mesh:

Substances:

Year:  2021        PMID: 33933294     DOI: 10.1016/j.nmd.2021.03.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  1 in total

1.  A custom ddPCR method for the detection of copy number variations in the nebulin triplicate region.

Authors:  Lydia Sagath; Vilma-Lotta Lehtokari; Carina Wallgren-Pettersson; Katarina Pelin; Kirsi Kiiski
Journal:  PLoS One       Date:  2022-05-16       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.